CareFirst opposes quick appeal in US antitrust case against Amgen
MLex Summary: CareFirst opposed Amgen’s petition for immediate appeal in a US antitrust case over the drug Enbrel, saying Amgen fails to establish that an interlocutory appeal would materially advance this...To view the full article, register now.
Already a subscriber? Click here to view full article